Elevated ALKBH5 expression has also been shown to contribute to the m6A modification of frizzled class receptor 10 (FZD10) mRNA and to the resistance of ovarian cancer cells to treatment with a poly-ADP ribose polymerase inhibitor, which may also be associated with altered FTO levels (28). This evidence concerns the gene ALKBH5 and ovarian carcinoma.